Pear Therapeutics’ reSET and reSET-O prescription digital therapeutics are available to Florida’s five million Medicaid patients via its Preferred Drug List as of this month.
Pear’s reSET, a mobile application used to help treat substance abuse, received FDA De Novo clearance in 2017. The Boston-based company’s reSET-O, used for opioid use disorder, received 510(k) clearance in 2018.
“The unmet need in addiction across the U.S. is enormous, and Florida represents an important step in how we are helping more and more patients by working with states to provide covered access to our products,” Julia Strandberg, chief commercial officer of Pear Therapeutics, said in a statement.
THE LARGER TREND
In November, Pear entered into a contract with the Wisconsin Department of Health Services to offer its reSET and reSET-O prescription digital therapeutics to participating providers within the state’s outpatient treatment settings, including programs that provide prescriptions for buprenorphine, a medicine used to treat opioid dependence.
Earlier this month, Spero Health announced its 99 outpatient substance abuse centers throughout Kentucky, Ohio, Indiana, Tennessee, Virginia and West Virginia would gain access to reSET and reSET-O.
The company was also awarded a contract from the California Department of Healthcare Services to support the implementation of a pilot program that provides motivational incentives to individuals with stimulant use disorder.
The publicly-traded company wasn’t immune to the many layoffs seen throughout the digital health sector last summer.
In July, Pear laid off approximately 25 of its employees, making up about 9% of its full-time workforce, due to the larger economic environment and the need to restructure operations to narrow its short-term business focus.
The layoff announcement came three months after Pear launched a program to offer its reSET and reSET-O offerings via telehealth providers. The first was Pursue Care, which focuses on addiction medicine.
